Dogwood Therapeutics Announces Third Quarter 2026 Financial Results
- Completed the Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy, top-line results to be announced in November 2026 -
GlobeNewsWire11/5/2026Neutral
DWTX
Dogwood Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$48.93M
P/E Ratio
0.58
EPS
$2.20
Beta
2.11
52W High
$7.04
52W Low
$0.90
50-Day MA
$1.56
200-Day MA
$1.94
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company is headquartered in Alpharetta, Georgia.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-29.56M |
| Operating Margin | 0.00% |
| Return on Equity | -47.80% |
| Return on Assets | -20.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.52 |
| Price-to-Book | 0.59 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.22 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $38.23M |
| Float | $1.71M |
| % Insiders | 84.63% |
| % Institutions | 11.47% |
Historical Volatility
HV 10-Day
147.24%
HV 20-Day
108.20%
HV 30-Day
92.26%
HV 60-Day
92.34%
HV Rank
68.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($14.00 target)
1
Strong Buy1
BuyLatest News
Dogwood to Participate in the 2026 Maxim Growth Summit
ATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that management will participate in the upcoming 2026 Maxim Growth Summit, taking place from October 12-14, 2026, in New York, NY. The conference brings together industry leaders, innovators, and investors to explore the latest trends and advancements across several industries.
GlobeNewsWire10/6/2026Neutral
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
- Enrollment of 239 Patients Meets Upper End of Planned Enrollment Target Range - - Topline Data Expected in November 2026 - ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced the completion of patient enrollment in its ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathic Pain (“CINP”) trial.
GlobeNewsWire9/14/2026Neutral
Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript
Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript
Seeking Alpha9/2/2026Neutral
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic pain (“CINP”). To register, click here.
GlobeNewsWire8/17/2026Neutral
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled –
GlobeNewsWire8/13/2026Neutral
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has successfully enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b trial. HAL-CINP remains on track for top-line data readout from the four-week study in the fall of 2026.
GlobeNewsWire7/20/2026Neutral
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026 Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026
GlobeNewsWire6/30/2026Neutral
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
Seeking Alpha6/16/2026Neutral
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package
GlobeNewsWire5/18/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DWTX and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 11/7/2026